Clinical trial NCT03417830: Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging
Official title: An Adaptive, Open-Label Study to Evaluate the Biodistribution of 89Zirconium-labelled GSK2398852 in the Heart and Other Organs of Patients With Transthyretin Cardiomyopathy (ATTR-CM) Using Positron Emission Tomography (PET) Imaging
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Amyloidosis
Keywords: miridesap
GSK2315698
89Zirconium labelled
Positron Emission Tomography
Transthyretin cardiomyopathy
GSK2398852
dezamizumab
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2018-01-31
Enrollment: 2
Sex: ALL
Minimum age (years): 65
Maximum age (years): 80
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Part A of the study will include 3 subjects with ATTR-CM who will participate in two dosing sessions and Part B of the study will include 3 subjects with ATTR-CM who will participate in one dosing session. A single dosing session will constitute treatment with carboxy pyrrolidine hexanoyl pyrrolidine carboxylate (CPHPC), total mass dose (TMD) administration of anti-serum amyloid P (SAP) monoclonal antibody (mAb) consisting of in vivo mixing of a single infusion of unlabeled anti-SAP mAb and a separate infusion of 89Zr-GSK2398852 via a different peripheral venous line, and up to 3 serial PET scanning procedures after administration of 89Zr-GSK2398852.
Primary purpose: DIAGNOSTIC

Brief summary: The principal aim of this study is to investigate the cardiac uptake of 89Zr-GSK2398852 in subjects with transthyretin cardiomyopathy amyloidosis (ATTR-CM), and its biodistribution to other organs. Low doses of GSK2398852 will be co-administered at levels not high enough for therapeutic benefit. This study will be conducted in two parts: Part A and Part B. Subjects in Part A will participate in up to two dosing sessions and subjects in Part B will participate in one dosing session. Subjects will undergo up to 3 PET scans at varying intervals after 89Zr-GSK2398852 administration. The total duration of study will be approximately 3 to 4 months for subjects in Part A and approximately 2 months for subjects in Part B. Part B of the study will be triggered based on data obtained in Part A and other emerging data.


Eligibility criteria: Inclusion Criteria:

* Subject must be 65 to 80 years of age inclusive, at the time of signing the informed consent.
* Subjects with a diagnosis of ATTR-CM: a) Wild-type ATTR status must be confirmed by genotyping and have one of the following: i) Definite histochemical identification of amyloid by Congo red staining and green birefringence in crossed polarized light in cardiac or other tissue biopsy and identification of Transthyretin amyloidosis (TTR) as the amyloid fibril protein either by immunohistochemistry or proteomic analysis OR ii) Scintigraphy Technetium-99m-labeled 3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) with confirmed myocardial uptake. b) Hereditary ATTR amyloidosis (example, TTR Val30Met) should have a known amyloidogenic TTR mutation demonstrated by genotyping and is recognized to be primarily associated with cardiomyopathy and one of the following: i) Definite histochemical identification of amyloid by Congo red staining and green birefringence in crossed polarized light in cardiac or other tissue biopsy and identification of TTR as the amyloid fibril protein either by immunohistochemistry or proteomic analysis. ii) Scintigraphy: 99mTc-DPD with confirmed myocardial uptake.
* Both male and female subjects are eligible to participate. a) Male subjects: A male subject must agree to use contraception during the treatment period and for at least 3 months after the last scan and refrain from donating sperm during this period. b) Female subjects: A female subject is eligible to participate if she is not of childbearing potential.
* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and protocol.
* New York Heart Association (NYHA) up to class 3; subjects should be clinically stable for at least 3 months preceding to Screening.

Exclusion Criteria:

* Cardiomyopathy primarily caused by non-amyloid diseases (example, ischemic heart disease; valvular heart disease).
* Interval from the Q wave on the ECG to point T using Fredericia's formula (QTcF) \>500 milliseconds (msec).
* Sustained (at a rate of \>=120 beats per minute for \>=30 seconds), or symptomatic monomorphic ventricular tachycardia (VT), or rapid polymorphic VT, at Screening/Baseline cardiac monitoring.
* Systolic blood pressure \<=100 millimeters of mercury (mm/Hg) based on triplicate readings at Screening.
* Unstable heart failure defined as emergency hospitalization for worsening, or decompensated heart failure, or syncopal episode within 1 month of screening.
* Implantable cardiac defibrillator (ICD) or permanent pacemaker (PPM) at Screening.
* Estimated Glomerular filtration rate (eGFR) at Screening \<50 milliliters per minute (mL/min) calculated using modification of diet in renal disease (MDRD).
* Any active and persistent dermatological condition, which in the opinion of the Investigator and Medical Monitor would preclude safe participation.
* History of allogeneic stem cell transplantation, prior solid organ transplant, or anticipated to undergo solid organ transplantation, or left ventricular assist device (LVAD) implantation.
* Malignancy within last 5 years, except for basal or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix that has been successfully treated.
* Acute coronary syndrome, or any form of coronary revascularization procedure (including coronary artery bypass grafting \[CABG\]), within 6 months of screening.
* Symptomatic, clinically significant autonomic neuropathy which the Principal Investigator (PI) feels will preclude administration of study treatment.
* Uncontrolled hypertension during Screening.
* ALT \>3 times upper limit of normal (ULN) OR bilirubin \>1.5 times ULN (isolated bilirubin \>1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
* Peripheral edema at Screening that in the opinion of the PI or designee might prevent adequate absorption of subcutaneously administered CPHPC.
* Presence of any co-morbid (example, steroid refractory rheumatoid arthritis), or an uncontrolled medical condition (example, diabetes mellitus), which in the opinion of the investigator would increase the potential risk to the subject. Investigator should liaise with the Medical Monitor where there is uncertainty as to the eligibility of a subject.
* Positive test for hepatitis B, hepatitis C and/or human immunodeficiency virus (HIV) during Screening, or within 3 months prior to first dose of study treatment.
* Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A \[IgA\] dermatosis, toxic epidermal necrolysis and exfoliative dermatitis).
* Inability to comprehend and/or understand the study patient information sheet, and/or unwillingness or inability to follow the procedures outlined in the protocol.
* Has any of the following: a) Fulfillment of diagnostic criteria for Amyloid Light-chain (AL) amyloidosis. b) Fulfillment of diagnostic criteria for amyloid A (AA) or non-TTR hereditary amyloidosis.
* ATTR Disease Load: c) Histologically proven or clinically suspected gastrointestinal TTR amyloidosis; d) Diffuse skeletal muscle uptake of 99m(Tc)-DPD on Single-photon emission computed tomography (SPECT) imaging (where available); e) Peripheral neuropathy causing more than mild morbidity (example, walking disability; neuropathic pain affecting activities of daily living); f) Proven or clinically suspected intracranial TTR involvement including ophthalmological disease.
* Non-amyloidosis related chronic liver disease (with the exception of Gilbert's syndrome or clinically asymptomatic gallstones).
* Participation in a separate clinical trial involving CPHPC within 3 months of Screening.
* Any prohibited concomitant medication within referenced timeframe.
* Treatment with another investigational drug, biological agent, or device within 6 months of screening, or 5 half-lives of the study agent, whichever is longer.
* Orthopnea of sufficient severity to preclude supine scanning as determined at Screening.
* Inability to fit inside scanner due to body size (girth).
* History of claustrophobia.
* Contraindication to magnetic resonance imaging (MRI) contrast agents.
* Contraindication for MRI scanning (as assessed by local MRI safety questionnaire), which includes but is not limited to: a) Intracranial aneurysm clips (except Sugita) or other metallic objects; b) Intra-orbital metal fragments that have not been removed; c) Pacemakers or other implanted cardiac rhythm management/monitoring devices and non-magnetic resonance (MR) conditional heart valves; d) Inner ear implants.
* Donation of blood or blood products in excess of 500 milliliters (mL) within 84 days of Screening.
* Poor or unsuitable venous access.

Primary outcomes:
measure: Part A- Session 1: Peak Standardized Uptake Values (SUV) in Focal Anatomical Regions of the Heart Following 80-200 mg Dose of Anti-SAP mAb
timeFrame: Session 1: Days 4, 5, 6 and 8
measure: Part A- Session 2: Peak SUV in Focal Anatomical Regions of the Heart Following Anti-SAP mAb Dose Between 200 mg and <=500 mg
timeFrame: Session 2: Days 3, 4 and 5
measure: Part B: Peak SUV in Focal Anatomical Regions of the Heart Following 80-200 mg Dose of Anti-SAP mAb
timeFrame: Days 3, 4 and 6
measure: Part B: Peak SUV in Focal Anatomical Regions of the Heart Following Anti-SAP mAb Dose Between 200 mg and <=500 mg
timeFrame: Days 3, 4 and 6
measure: Part A- Session 1: Mean SUV of Whole Heart Following 80-200 mg Dose of Anti-SAP mAb
timeFrame: Session 1: Days 4, 5, 6 and 8
measure: Part A- Session 2: Mean SUV of Whole Heart Following Anti-SAP mAb Dose Between 200 mg and <=500 mg
timeFrame: Session 2: Days 3, 4 and 5
measure: Part B: Mean SUV of Whole Heart Following 80-200 mg Dose of Anti-SAP mAb
timeFrame: Days 3, 4 and 6
measure: Part B: Mean SUV of Whole Heart Following Anti-SAP mAb Dose Between 200 mg and <=500 mg
timeFrame: Days 3, 4 and 6
Secondary outcomes:
measure: Part A- Session 1: Mean SUV of Focal Radioactivity Uptake After 80-200 mg Dose of Anti-SAP mAb
timeFrame: Session 1: Days 4, 5, 6 and 8
measure: Part A- Session 1: Mean SUV of Focal Radioactivity Uptake After 80-200 mg Dose of Anti-SAP mAb: Thyriod Gland-goitre Hotspot
timeFrame: Session 1: Days 4 and 6
measure: Part A- Session 2: Mean SUV of Focal Radioactivity Uptake After Anti-SAP mAb Dose Between 200 mg and <=500 mg
timeFrame: Session 2: Days 3, 4 and 5
measure: Part B: Mean SUV of Focal Radioactivity Uptake After 80-200 mg Dose of Anti-SAP mAb
timeFrame: Days 3, 4 and 6
measure: Part B: Mean SUV of Focal Radioactivity Uptake After Anti-SAP mAb Dose Between 200 mg and <=500 mg
timeFrame: Days 3, 4 and 6
measure: Part A- Session 1: Mean SUV of Total Radioactivity Uptake After 80-200 mg Dose of Anti-SAP mAb
timeFrame: Session 1: Days 4, 5, 6 and 8
measure: Part A- Session 1: Mean SUV of Total Radioactivity Uptake After 80-200 mg Dose of Anti-SAP mAb: Thyroid Gland-goitre
timeFrame: Session 1: Days 4 and 6
measure: Part A- Session 1: Mean SUV of Total Radioactivity Uptake After 80-200 mg Dose of Anti-SAP mAb: Testes
timeFrame: Session 1: Days 4, 5 and 8
measure: Part A- Session 2: Mean SUV of Total Radioactivity Uptake After Anti-SAP mAb Dose Between 200 mg and <=500 mg
timeFrame: Session 2: Days 3, 4, and 5
measure: Part B: Mean SUV of Total Radioactivity Uptake After 80-200 mg Dose of Anti-SAP mAb
timeFrame: Days 3, 4 and 6
measure: Part B: Mean SUV of Total Radioactivity Uptake After an Anti-SAP mAb Dose Between 200 mg and <=500 mg
timeFrame: Days 3, 4 and 6
measure: Part A: Maximum Concentration in Plasma (Cmax) of Total mAb
timeFrame: Sessions 1 and 2: Day 3 (pre-dose, halfway infusion, end of infusion, 4 and 7 hours after end of infusion), Days 4, 5, 6 and 7
measure: Part B: Cmax of Total mAb
timeFrame: Day 3 (pre-dose, end of infusion, 4 and 7 hours post-infusion), Days 4, 5, 6, 7 and 8
measure: Part A: Time Associated With Cmax (Tmax) of Total mAb
timeFrame: Sessions 1 and 2: Day 3 (pre-dose, halfway infusion, end of infusion, 4 and 7 hours after end of infusion), Days 4, 5, 6 and 7
measure: Part B: Tmax of Total mAb
timeFrame: Day 3 (pre-dose, end of infusion, 4 and 7 hours post-infusion), Days 4, 5, 6, 7 and 8
measure: Part A: Clearance of Total mAb
timeFrame: Sessions 1 and 2: Day 3 (pre-dose, halfway infusion, end of infusion, 4 and 7 hours after end of infusion), Days 4, 5, 6 and 7
measure: Part B: Clearance of Total mAb
timeFrame: Day 3 (pre-dose, end of infusion, 4 and 7 hours post-infusion), Days 4, 5, 6, 7 and 8
measure: Part A: Terminal Half-life (T1/2) of Total mAb
timeFrame: Sessions 1 and 2: Day 3 (pre-dose, halfway infusion, end of infusion, 4 and 7 hours after end of infusion), Days 4, 5, 6 and 7
measure: Part B: T1/2 of Total mAb
timeFrame: Day 3 (pre-dose, end of infusion, 4 and 7 hours post-infusion), Days 4, 5, 6, 7 and 8
measure: Part A:Area Under the Concentration Time Curve Till Last Observation (AUC[0 to t]) of Total mAb
timeFrame: Sessions 1 and 2: Day 3 (pre-dose, halfway infusion, end of infusion, 4 and 7 hours after end of infusion), Days 4, 5, 6 and 7
measure: Part B: AUC(0 to t) of Total mAb
timeFrame: Day 3 (pre-dose, end of infusion, 4 and 7 hours post-infusion), Days 4, 5, 6, 7 and 8
measure: Part A: Area Under the Concentration Time Curve Till Time Infinity (AUC[0 to Infinity]) of Total mAb
timeFrame: Sessions 1 and 2: Day 3 (pre-dose, halfway infusion, end of infusion, 4 and 7 hours after end of infusion), Days 4, 5, 6 and 7
measure: Part B: AUC(0 to Infinity) of Total mAb
timeFrame: Day 3 (pre-dose, end of infusion, 4 and 7 hours post-infusion), Days 4, 5, 6, 7 and 8
measure: Part A: Cmax of 89Zr-GSK2398852 PKs of Radioactivity (Radio-PK)
timeFrame: Sessions 1 and 2: Day 3 (10 minutes, 60 minutes, 4 hours, 7 hours post-dose), Days 4, 5 and 6
measure: Part B: Cmax of 89Zr-GSK2398852 Radio-PK
timeFrame: Day 3 (10 minutes, 60 minutes, 4 hours, 7 hours post-dose), Days 4, 5 and 6
measure: Part A: Tmax of 89Zr- GSK2398852 Radio-PK
timeFrame: Sessions 1 and 2: Day 3 (10 minutes, 60 minutes, 4 hours, 7 hours post-dose), Days 4, 5 and 6
measure: Part B: Tmax of 89Zr-GSK2398852 Radio-PK
timeFrame: Day 3 (10 minutes, 60 minutes, 4 hours, 7 hours post-dose), Days 4, 5 and 6
measure: Part A: T1/2 of 89Zr- GSK2398852 Radio-PK
timeFrame: Sessions 1 and 2: Day 3 (10 minutes, 60 minutes, 4 hours, 7 hours post-dose), Days 4, 5 and 6
measure: Part B: T1/2 of 89Zr- GSK2398852 Radio-PK
timeFrame: Day 3 (10 minutes, 60 minutes, 4 hours, 7 hours post-dose), Days 4, 5 and 6
measure: Part A: AUC(0 to t) of 89Zr- GSK2398852 Radio-PK
timeFrame: Sessions 1 and 2: Day 3 (10 minutes, 60 minutes, 4 hours, 7 hours post-dose), Days 4, 5 and 6
measure: Part B: AUC(0 to t) of 89Zr- GSK2398852 Radio-PK
timeFrame: Day 3 (10 minutes, 60 minutes, 4 hours, 7 hours post-dose), Days 4, 5 and 6
measure: Part A: AUC(0 to Infinity) of 89Zr- GSK2398852 Radio-PK
timeFrame: Sessions 1 and 2: Day 3 (10 minutes, 60 minutes, 4 hours, 7 hours post-dose), Days 4, 5 and 6
measure: Part B: AUC(0 to Infinity) of 89Zr- GSK2398852 Radio-PK
timeFrame: Day 3 (10 minutes, 60 minutes, 4 hours, 7 hours post-dose), Days 4, 5 and 6
measure: Part A: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
timeFrame: Up to Day 26 of the last session
measure: Part B: Number of Participants With AEs and SAEs
timeFrame: Up to Day 26
measure: Part A: Number of Participants With Skin Rashes
timeFrame: Up to Day 26 of the last session
measure: Part B: Number of Participants With Skin Rashes
timeFrame: Up to Day 26
measure: Part A: Number of Participants With Cardiac Adverse Events
timeFrame: Up to Day 26 of the last session
measure: Part B: Number of Participants With Cardiac Adverse Events
timeFrame: Up to Day 26
measure: Part A: Number of Participants With Infusion Related Reactions
timeFrame: Up to Day 26 of the last session
measure: Part B: Number of Participants With Infusion Related Reactions
timeFrame: Up to Day 26
measure: Part A: Change From Baseline in Cardiac Troponin T and N-terminal Prohormone of Brain Natriuretic Peptide (NT-ProBNP)
timeFrame: Session 1: Baseline (Day 1 Pre-dose), Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 26; Session 2: Day 1- Pre-dose, Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 26
measure: Part B: Change From Baseline in Cardiac Troponin T and NT-ProBNP
timeFrame: Baseline and up to Day 26
measure: Part A: Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings
timeFrame: Up to Day 26 of the last session
measure: Part B: Number of Participants With Abnormal 12-lead ECG Findings
timeFrame: Up to Day 26
measure: Part A: Number of Participants With Abnormal Inpatient Cardiac Telemetry
timeFrame: Up to Day 26 of the last session
measure: Part B: Number of Participants With Abnormal Inpatient Cardiac Telemetry
timeFrame: Up to Day 26
measure: Part A: Number of Participants With Abnormal Outpatient Cardiac Telemetry
timeFrame: Up to Day 26 of the last session
measure: Part B: Number of Participants With Abnormal Outpatient Cardiac Telemetry
timeFrame: Up to Day 26
measure: Part A: Number of Participants With Abnormal Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
timeFrame: Up to Day 26 of the last session
measure: Part B: Number of Participants With Abnormal SBP and DBP
timeFrame: Up to Day 26
measure: Part A: Number of Participants With Abnormal Temperature
timeFrame: Up to Day 26 of the last session
measure: Part B: Number of Participants With Abnormal Temperature
timeFrame: Up to Day 26
measure: Part A: Number of Participants With Abnormal Respiratory Rate
timeFrame: Up to Day 26 of the last session
measure: Part B: Number of Participants With Abnormal Respiratory Rate
timeFrame: Up to Day 26
measure: Part A: Number of Participants With Abnormal Pulse Rate
timeFrame: Up to Day 26 of the last session
measure: Part B: Number of Participants With Abnormal Pulse Rate
timeFrame: Up to Day 26
measure: Part A: Number of Participants With New Abnormal Physical Examination Findings
timeFrame: Session 1: At screening (within 35 days of Anti-SAP treatment of session 1), Day 1 Pre-dose, Day 3, Day 5, Day 8 and Day 11; Session 2: Day 1 Pre-dose, Day 3, Day 5, Day 8 and Day 11
measure: Part B: Number of Participants With New Abnormal Physical Examination Findings
timeFrame: At screening (within 35 days of Anti-SAP treatment), Days 1, 3, 5, 8 and 11
measure: Part A: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets
timeFrame: Session 1: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26; Session 2: Day 1-Pre-dose, Days 3, 5, 7, 10 and 26
measure: Part B: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets
timeFrame: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26
measure: Part A: Change From Baseline in Hematology Parameter: Hematocrit
timeFrame: Session 1: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26; Session 2: Day 1-Pre-dose, Days 3, 5, 7, 10 and 26
measure: Part B: Change From Baseline in Hematology Parameter: Hematocrit
timeFrame: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26
measure: Part A: Change From Baseline in Hematology Parameter: Hemoglobin
timeFrame: Session 1: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26; Session 2: Day 1- Pre-dose, Days 3, 5, 7, 10 and 26
measure: Part B: Change From Baseline in Hematology Parameter: Hemoglobin
timeFrame: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26
measure: Part A: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
timeFrame: Session 1: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26; Session 2: Day 1- Pre-dose, Days 3, 5, 7, 10 and 26
measure: Part B: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
timeFrame: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26
measure: Part A: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
timeFrame: Session 1: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26; Session 2: Day 1- Pre-dose, Days 3, 5, 7, 10 and 26
measure: Part B: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
timeFrame: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26
measure: Part A: Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes
timeFrame: Session 1: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26; Session 2: Day 1- Pre-dose, Days 3, 5, 7, 10 and 26
measure: Part B: Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes
timeFrame: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26
measure: Part A: Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea
timeFrame: Session 1: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26; Session 2: Day 1- Pre-dose, Days 3, 5, 7, 10 and 26
measure: Part B: Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea
timeFrame: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26
measure: Part A: Change From Baseline in Chemistry Parameters: Albumin, Protein
timeFrame: Session 1: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26; Session 2: Day 1- Pre-dose, Days 3, 5, 7, 10 and 26
measure: Part B: Change From Baseline in Chemistry Parameters: Albumin, Protein
timeFrame: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26
measure: Part A: Change From Baseline in Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST)
timeFrame: Session 1: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26; Session 2: Day 1- Pre-dose, Days 3, 5, 7, 10 and 26
measure: Part B: Change From Baseline in Chemistry Parameters: ALP, ALT, AST
timeFrame: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26
measure: Part A: Change From Baseline in Chemistry Parameters: Direct Bilirubin, Bilirubin, Creatinine
timeFrame: Session 1: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26; Session 2: Day 1- Pre-dose, Days 3, 5, 7, 10 and 26
measure: Part B: Change From Baseline in Chemistry Parameters: Direct Bilirubin, Bilirubin, Creatinine
timeFrame: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26
measure: Part A: Number of Participants With Abnormal Urinalysis Parameters: Glucose, Protein, Blood, Ketones
timeFrame: Up to Day 26 of the last session
measure: Part A: Number of Participants With Abnormal Urinalysis Parameters: Specific Gravity, Potential of Hydrogen
timeFrame: Up to Day 26 of the last session
measure: Part B: Number of Participants With Abnormal Urinalysis Parameters: Glucose, Protein, Blood, Ketones
timeFrame: Up to Day 26
measure: Part B: Number of Participants With Abnormal Urinalysis Parameters: Specific Gravity, Potential of Hydrogen
timeFrame: Up to Day 26
Other outcomes:
Locations:
city: Uppsala
country: Sweden
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
citation: Wechalekar A, Antoni G, Al Azzam W, Bergstrom M, Biswas S, Chen C, Cheriyan J, Cleveland M, Cookson L, Galette P, Janiczek RL, Kwong RY, Lukas MA, Millns H, Richards D, Schneider I, Solomon SD, Sorensen J, Storey J, Thompson D, van Dongen G, Vugts DJ, Wall A, Wikstrom G, Falk RH. Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study. BMC Cardiovasc Disord. 2022 Feb 13;22(1):49. doi: 10.1186/s12872-021-02407-6.